Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Vrang

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Antimicrobial Agents and Chemotherapy|May 1, 1989
Inhibition of human immunodeficiency virus in vitro by combinations of 3'-azido-3'-deoxythymidine and foscarnetR Koshida, L Vrang, G Gilljam, et al.
Experimental Cell Research|May 8, 1998
Protein tyrosine kinases p53/56lyn and p72syk in MHC class I-mediated signal transduction in B lymphoma cellsA E Pedersen, S Bregenholt, S Skov, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
Synthesis and anti-HIV activities of urea-PETT analogs belonging to a new class of potent non-nucleoside HIV-1 reverse transcriptase inhibitorsC Sahlberg, R Noréen, P Engelhardt, et al.
Antimicrobial Agents and Chemotherapy|November 26, 1997
Human immunodeficiency virus type 1 proteinase resistance to symmetric cyclic urea inhibitor analogsU Nillroth, L Vrang, P O Markgren, et al.
Antiviral Research|December 1, 1995
Inhibition of human immunodeficiency virus type 1 wild-type and mutant reverse transcriptases by the phenyl ethyl thiazolyl thiourea derivatives trovirdine and MSC-127H Zhang, L Vrang, K Bäckbro, et al.
AIDS (London, England)|February 1, 1997
Prevention of simian immunodeficiency virus, SIVsm, or HIV-2 infection in cynomolgus monkeys by pre- and postexposure administration of BEA-005D Böttiger, N G Johansson, B Samuelsson, et al.
Antiviral Chemistry & Chemotherapy|January 6, 1999
Colorimetric assays for evaluation of the mode of action of human immunodeficiency virus type 1 non-nucleoside reverse transcriptase inhibitorsX Shao, A S Rytting, D H Ekstrand, et al.
Virology|October 1, 1993
Disruption of a salt bridge between Asp 488 and Lys 465 in HIV-1 reverse transcriptase alters its proteolytic processing and polymerase activityL Goobar-Larsson, K Bäckbro, T Unge, et al.
Journal of Biomolecular Screening|November 18, 2000
Characterization of a set of HIV-1 protease inhibitors using binding kinetics data from a biosensor-based screenM D Hämäläinen, P O Markgren, W Schaal, et al.
Journal of Medicinal Chemistry|September 7, 2001
Design and synthesis of potent C(2)-symmetric diol-based HIV-1 protease inhibitors: effects of fluoro substitutionD Pyring, J Lindberg, Rosenquist A, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Antimicrobial Agents and Chemotherapy|May 1, 1989
Inhibition of human immunodeficiency virus in vitro by combinations of 3'-azido-3'-deoxythymidine and foscarnetR Koshida, L Vrang, G Gilljam, et al.
Experimental Cell Research|May 8, 1998
Protein tyrosine kinases p53/56lyn and p72syk in MHC class I-mediated signal transduction in B lymphoma cellsA E Pedersen, S Bregenholt, S Skov, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
Synthesis and anti-HIV activities of urea-PETT analogs belonging to a new class of potent non-nucleoside HIV-1 reverse transcriptase inhibitorsC Sahlberg, R Noréen, P Engelhardt, et al.
Antimicrobial Agents and Chemotherapy|November 26, 1997
Human immunodeficiency virus type 1 proteinase resistance to symmetric cyclic urea inhibitor analogsU Nillroth, L Vrang, P O Markgren, et al.
Antiviral Research|December 1, 1995
Inhibition of human immunodeficiency virus type 1 wild-type and mutant reverse transcriptases by the phenyl ethyl thiazolyl thiourea derivatives trovirdine and MSC-127H Zhang, L Vrang, K Bäckbro, et al.
AIDS (London, England)|February 1, 1997
Prevention of simian immunodeficiency virus, SIVsm, or HIV-2 infection in cynomolgus monkeys by pre- and postexposure administration of BEA-005D Böttiger, N G Johansson, B Samuelsson, et al.
Antiviral Chemistry & Chemotherapy|January 6, 1999
Colorimetric assays for evaluation of the mode of action of human immunodeficiency virus type 1 non-nucleoside reverse transcriptase inhibitorsX Shao, A S Rytting, D H Ekstrand, et al.
Virology|October 1, 1993
Disruption of a salt bridge between Asp 488 and Lys 465 in HIV-1 reverse transcriptase alters its proteolytic processing and polymerase activityL Goobar-Larsson, K Bäckbro, T Unge, et al.
Journal of Biomolecular Screening|November 18, 2000
Characterization of a set of HIV-1 protease inhibitors using binding kinetics data from a biosensor-based screenM D Hämäläinen, P O Markgren, W Schaal, et al.
Journal of Medicinal Chemistry|September 7, 2001
Design and synthesis of potent C(2)-symmetric diol-based HIV-1 protease inhibitors: effects of fluoro substitutionD Pyring, J Lindberg, Rosenquist A, et al.
Pageof 3